Electronic Patient-Reported Outcomes

Global Electronic Patient-Reported Outcomes Market to Reach US$2.2 Billion by 2030

The global market for Electronic Patient-Reported Outcomes estimated at US$953.7 Million in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 14.7% over the analysis period 2024-2030. Cloud Based, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the On-Premise segment is estimated at 17.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$259.8 Million While China is Forecast to Grow at 19.3% CAGR

The Electronic Patient-Reported Outcomes market in the U.S. is estimated at US$259.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$462.4 Million by the year 2030 trailing a CAGR of 19.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Global Electronic Patient-Reported Outcomes (ePRO) Market – Key Trends & Drivers Summarized

Why Are Electronic Patient-Reported Outcomes Revolutionizing Clinical Research and Care Models?

The shift toward electronic patient-reported outcomes (ePRO) represents a transformative pivot in how healthcare data is captured, validated, and integrated across the clinical research and care continuum. ePRO solutions digitize the collection of patient-generated health data, enabling real-time, remote capture of symptoms, treatment responses, quality of life indicators, and more—all directly from the patient without clinician interpretation. This move away from paper-based methods addresses long-standing inefficiencies including transcription errors, incomplete data, and lag times between entry and analysis.

Clinical trials are increasingly incorporating ePRO systems to meet regulatory demands for high-integrity data and patient-centric endpoints. Unlike traditional methods, ePROs facilitate timestamped, geolocated, and audit-trailed entries, reducing recall bias and enhancing data granularity. As the FDA and EMA continue advocating for real-world evidence and patient-centric approaches in regulatory submissions, the adoption of ePRO platforms is becoming a non-negotiable asset in modern drug development pipelines. Pharmaceutical sponsors and CROs are standardizing ePRO modules across trial phases to streamline multi-site data collection, especially in decentralized and hybrid clinical trials.

In chronic care and post-marketing surveillance, ePROs are being adopted to improve symptom tracking, medication adherence, and quality of life monitoring. Real-time insights into patient-reported fatigue, pain, or mood enable physicians to intervene sooner and personalize care strategies. The pandemic significantly accelerated this shift, normalizing digital health engagement and remote monitoring tools as acceptable standards of care. Health systems now recognize the value of integrating ePROs into electronic health records (EHRs) to enrich longitudinal datasets and enable more predictive, population-level insights.

How Are Technology and Integration Standards Driving Market Sophistication?

The ePRO landscape is being shaped by rapidly advancing technologies in mobile computing, cloud infrastructure, and interoperability frameworks. Contemporary ePRO solutions are increasingly device-agnostic and accessible via smartphones, tablets, and wearables, with support for offline data capture and multi-language localization. These platforms integrate seamlessly with patient portals, EHR systems, and electronic clinical outcome assessments (eCOA) suites, enabling end-to-end digital workflows from consent to compliance tracking.

Interoperability remains central to ePRO adoption. HL7 FHIR (Fast Healthcare Interoperability Resources) standards are being leveraged to integrate ePRO data into clinical care pathways and research databases. Leading providers are offering APIs for seamless data exchange with EDC (electronic data capture) systems, analytics dashboards, and AI engines. These integrations not only reduce manual data migration but also support real-time decision-making across care teams and study monitors.

Security and compliance are evolving in parallel. HIPAA, GDPR, and 21 CFR Part 11 compliance are table stakes for ePRO vendors. Solutions are now built with end-to-end encryption, biometric authentication, and automated audit logging to meet global regulatory requirements. Furthermore, the emergence of AI-enabled data validation, sentiment analysis, and natural language processing is expanding the capabilities of ePROs beyond structured surveys, allowing for the capture of unstructured symptom narratives and free-text diary entries—enhancing patient voice fidelity across settings.

Which End-User Segments and Therapeutic Areas Are Leading ePRO Utilization?

Pharmaceutical and biotechnology companies constitute the largest adopters of ePRO solutions, particularly in late-phase and post-approval clinical trials. Oncology, immunology, and neurology are at the forefront, as these domains require nuanced, patient-experienced symptom tracking that traditional clinician assessments often fail to capture. Trials for multiple sclerosis, depression, and rheumatoid arthritis increasingly rely on ePROs to monitor fatigue, pain intensity, and emotional wellbeing on a continuous basis.

Hospitals, specialty clinics, and academic research institutions are following suit, especially as value-based care mandates grow. In oncology centers, for instance, patients are now routinely completing ePRO modules between treatment cycles to capture real-time feedback on nausea, sleep quality, and functional limitations. This data is automatically ingested into EHRs, enabling oncologists to adjust regimens or supportive care strategies before symptoms become unmanageable. Similarly, behavioral health clinics use ePROs for mood tracking, anxiety screening, and therapy response evaluation in outpatient settings.

Payors and health plans are beginning to explore ePRO integration within digital health ecosystems to stratify risk and support chronic disease management. For example, Medicare Advantage plans are evaluating PRO scores for conditions like COPD and diabetes to guide care coordination and incentivize preventive actions. Meanwhile, patient advocacy groups and nonprofit research organizations are adopting open-source ePRO tools to democratize access to patient-centric evidence, particularly in underrepresented or rare disease communities.

What Forces Are Fueling the Expansion of the ePRO Market Worldwide?

The growth in the electronic patient-reported outcomes (ePRO) market is driven by several factors including the global shift to decentralized clinical trials, rising demand for patient-centric care delivery, regulatory mandates favoring digital endpoints, and increasing investments in digital health infrastructure across emerging economies.

Decentralized clinical trial models, which surged during the COVID-19 pandemic, have cemented the role of ePROs in remote patient engagement and data collection. Pharmaceutical companies now demand tools that support multi-geography, multi-language data capture with minimal site dependency. This has triggered rapid platform innovation and global vendor expansion. Furthermore, hybrid care models in hospital systems are requiring that digital tools complement in-person visits, creating permanent demand for asynchronous, patient-initiated symptom reporting.

Regulatory agencies are playing a catalytic role by incentivizing the use of patient-reported outcomes in approval processes. The FDA’s guidance on incorporating clinical outcome assessments, including ePROs, in endpoint hierarchies has spurred R&D teams to include digital PRO data early in trial design. Reimbursement frameworks are also evolving to support digital engagement, especially under value-based care and remote patient monitoring codes.

Digital literacy, mobile penetration, and cloud access in developing regions are unlocking new markets. Governments in Asia-Pacific, Latin America, and Africa are piloting ePRO-based community health programs focused on maternal care, tuberculosis, and HIV. These initiatives aim to fill clinical data gaps while empowering local populations with mobile tools. Combined with decreasing hardware costs and open-source software ecosystems, this democratization trend is expected to expand the ePRO market well beyond its traditional pharmaceutical and hospital base.

SCOPE OF STUDY:

The report analyzes the Electronic Patient-Reported Outcomes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Delivery Mode (Cloud Based, On-Premise); Application (Oncology Application, Respiratory Application); End-Use (Contract Research Organizations End-Use, Pharmaceutical Companies End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -
  • 4G Clinical
  • ArisGlobal
  • Castor
  • Clario
  • Climedo Health GmbH
  • ClinCapture
  • Clinical Ink
  • Clinion
  • Cloudbyz
  • Curebase
  • EvidentIQ Group GmbH
  • Healthentia
  • ICON Plc
  • IQVIA
  • Kayentis
  • Medable Inc.
  • Medidata Solutions
  • Merative
  • Oracle Corporation
  • Parexel International
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Electronic Patient-Reported Outcomes – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Shift Toward Patient-Centric Clinical Trials Throws the Spotlight on ePRO Technologies
Growth in Decentralized and Hybrid Trial Models Drives Adoption of Remote Patient Reporting Tools
Regulatory Push for Real-World Evidence Collection Strengthens Business Case for ePRO Platforms
Increased Patient Engagement Requirements Spur Development of Mobile-Friendly ePRO Interfaces
Integration With Wearables and Health Apps Enhances Real-Time Symptom and QoL Tracking
Emergence of BYOD (Bring Your Own Device) Models Expands Accessibility of ePRO Tools
Expansion of Chronic Disease Management Programs Fuels Longitudinal Data Collection Needs
Globalization of Clinical Trials Encourages Multilingual and Regionally Compliant ePRO Systems
Demand for Faster Patient Enrollment and Reduced Dropouts Supports Digital Engagement Platforms
Regulatory Support From FDA and EMA Enhances Validation and Adoption of ePRO in Submissions
Growth in Oncology and CNS Trials Propels Use of Standardized PROMs Through ePRO Solutions
Partnerships Between CROs and Tech Providers Accelerate Custom Deployment Models
Development of AI and NLP Capabilities in ePRO Platforms Improves Unstructured Data Analysis
Integration With eConsent, eCRF, and EDC Systems Promotes End-to-End Trial Digitization
Use of Gamification and Reminders in ePRO Apps Boosts Patient Adherence and Data Quality
Rise in Patient-Centered Outcome Measures Drives Custom Questionnaire Design Tools
Use in Post-Marketing Surveillance and Real-World Outcomes Research Expands Commercial Applications
Data Security and HIPAA/GDPR Compliance Requirements Propel Encrypted Cloud-Based Platforms
Biopharma Investments in Digital Health Ecosystems Accelerate Acquisition and Licensing of ePRO Tools
Consumerization of Healthcare Experiences Spurs Intuitive UX and UI Improvements in ePRO Platforms
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Electronic Patient-Reported Outcomes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Electronic Patient-Reported Outcomes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Electronic Patient-Reported Outcomes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Cloud Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Cloud Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Cloud Based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for On-Premise by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Respiratory Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: USA 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: Canada 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: Canada 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
JAPAN
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: Japan 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: Japan 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 47: Japan Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: Japan 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
CHINA
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 50: China Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: China 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 53: China Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: China Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: China 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 56: China Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: China Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: China 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
EUROPE
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 59: Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Electronic Patient-Reported Outcomes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 65: Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
FRANCE
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 71: France Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: France Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: France 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 74: France Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: France Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: France 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 77: France Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: France Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: France 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
GERMANY
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 80: Germany Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Germany Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: Germany 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 83: Germany Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Germany Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Germany 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 86: Germany Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: Germany 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
ITALY
TABLE 89: Italy Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Italy Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: Italy 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 92: Italy Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Italy Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: Italy 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 95: Italy Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Italy 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
UNITED KINGDOM
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 98: UK Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: UK Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: UK 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 101: UK Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: UK Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: UK 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 104: UK Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: UK Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: UK 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
SPAIN
TABLE 107: Spain Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Spain Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Spain 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 110: Spain Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Spain Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Spain 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 113: Spain Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Spain Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: Spain 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
RUSSIA
TABLE 116: Russia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Russia Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: Russia 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 119: Russia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: Russia Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: Russia 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 122: Russia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Russia Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: Russia 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Rest of Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Europe 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
AUSTRALIA
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 146: Australia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Australia Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Australia 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 149: Australia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Australia Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Australia 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 152: Australia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Australia Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Australia 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
INDIA
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 155: India Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: India Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: India 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 158: India Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: India Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: India 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 161: India Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: India Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: India 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 164: South Korea Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: South Korea Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: South Korea 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 167: South Korea Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: South Korea Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: South Korea 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 170: South Korea Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: South Korea Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: South Korea 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 173: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Rest of Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: Rest of Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Rest of Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: Rest of Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Asia-Pacific Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
LATIN AMERICA
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 182: Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 183: Latin America Historic Review for Electronic Patient-Reported Outcomes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 185: Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Latin America Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 188: Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Latin America Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 191: Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 194: Argentina Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Argentina Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: Argentina 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 197: Argentina Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Argentina Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Argentina 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 200: Argentina Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Argentina Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Argentina 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
BRAZIL
TABLE 203: Brazil Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Brazil Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Brazil 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 206: Brazil Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Brazil Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Brazil 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 209: Brazil Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Brazil Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 211: Brazil 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
MEXICO
TABLE 212: Mexico Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Mexico Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 214: Mexico 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 215: Mexico Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Mexico Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 217: Mexico 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 218: Mexico Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Mexico Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 220: Mexico 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 221: Rest of Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Rest of Latin America Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 223: Rest of Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Rest of Latin America Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 226: Rest of Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Rest of Latin America Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 229: Rest of Latin America 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
MIDDLE EAST
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 230: Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 231: Middle East Historic Review for Electronic Patient-Reported Outcomes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 232: Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 233: Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Middle East Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 235: Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 236: Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Middle East Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 238: Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 239: Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 241: Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
IRAN
TABLE 242: Iran Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Iran Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 244: Iran 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 245: Iran Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: Iran Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 247: Iran 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 248: Iran Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Iran Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 250: Iran 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
ISRAEL
TABLE 251: Israel Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Israel Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 253: Israel 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 254: Israel Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Israel Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 256: Israel 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 257: Israel Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Israel Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 259: Israel 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 260: Saudi Arabia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Saudi Arabia Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 262: Saudi Arabia 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Saudi Arabia Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 265: Saudi Arabia 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Saudi Arabia Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 268: Saudi Arabia 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 269: UAE Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: UAE Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 271: UAE 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 272: UAE Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: UAE Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 274: UAE 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 275: UAE Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: UAE Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 277: UAE 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 278: Rest of Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Rest of Middle East Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 280: Rest of Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Rest of Middle East Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 283: Rest of Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: Rest of Middle East Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 286: Rest of Middle East 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
AFRICA
Electronic Patient-Reported Outcomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 287: Africa Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: Africa Historic Review for Electronic Patient-Reported Outcomes by Delivery mode - Cloud Based and On-Premise Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 289: Africa 16-Year Perspective for Electronic Patient-Reported Outcomes by Delivery mode - Percentage Breakdown of Value Sales for Cloud Based and On-Premise for the Years 2014, 2025 & 2030
TABLE 290: Africa Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: Africa Historic Review for Electronic Patient-Reported Outcomes by Application - Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 292: Africa 16-Year Perspective for Electronic Patient-Reported Outcomes by Application - Percentage Breakdown of Value Sales for Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
TABLE 293: Africa Recent Past, Current & Future Analysis for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Africa Historic Review for Electronic Patient-Reported Outcomes by End-Use - Contract Research Organizations End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 295: Africa 16-Year Perspective for Electronic Patient-Reported Outcomes by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2025 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings